Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments
-
Published:2024-04-08
Issue:1
Volume:15
Page:
-
ISSN:2042-6410
-
Container-title:Biology of Sex Differences
-
language:en
-
Short-container-title:Biol Sex Differ
Author:
Fernández-Arjona María del Mar, Navarro Juan Antonio, López-Gambero Antonio Jesús, de Ceglia Marialuisa, Rodríguez Miguel, Rubio Leticia, Rodríguez de Fonseca Fernando, Barrios Vicente, Chowen Julie A., Argente Jesús, Rivera Patricia, Suárez JuanORCID
Abstract
Abstract
Background
Children with pregnancy-associated plasma protein-A2 (PAPP-A2) mutations resulting in low levels of bioactive insulin-like growth factor-1 (IGF1) and progressive postnatal growth retardation have improved growth velocity and height following recombinant human (rh)IGF1 treatment. The present study aimed to evaluate whether Pappa2 deficiency and pharmacological manipulation of GH/IGF1 system are associated with sex-specific differences in growth-related signaling pathways.
Methods
Plasma, hypothalamus, pituitary gland and liver of Pappa2ko/ko mice of both sexes, showing reduced skeletal growth, and liver of these mice treated with rhGH, rhIGF1 and rhPAPP-A2 from postnatal day (PND) 5 to PND35 were analyzed.
Results
Reduced body and femur length of Pappa2ko/ko mice was associated with increases in: (1) components of IGF1 ternary complexes (IGF1, IGFBP5/Igfbp5, Igfbp3, Igfals) in plasma, hypothalamus and/or liver; and (2) key signaling regulators (phosphorylated PI3K, AKT, mTOR, GSK3β, ERK1/2 and AMPKα) in hypothalamus, pituitary gland and/or liver, with Pappa2ko/ko females having a more prominent effect. Compared to rhGH and rhIGF1, rhPAPP-A2 specifically induced: (1) increased body and femur length, and reduced plasma total IGF1 and IGFBP5 concentrations in Pappa2ko/ko females; and (2) increased Igf1 and Igf1r levels and decreased Ghr, Igfbp3 and Igfals levels in the liver of Pappa2ko/ko females. These changes were accompanied by lower phospho-STAT5, phospho-AKT and phospho-ERK2 levels and higher phospho-AMPK levels in the liver of Pappa2ko/ko females.
Conclusions
Sex-specific differences in IGF1 system and signaling pathways are associated with Pappa2 deficiency, pointing to rhPAPP-A2 as a promising drug to alleviate postnatal growth retardation underlying low IGF1 bioavailability in a female-specific manner.
Funder
Ministerio de Ciencia e Innovación Instituto de Salud Carlos III Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía
Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. Dauber A, Muñoz-Calvo MT, Barrios V, Domené HM, Kloverpris S, Serra-Juhé C, Desikan V, Pozo J, Muzumdar R, Martos-Moreno GÁ, Hawkins F, Jasper HG, Conover CA, Frystyk J, Yakar S, Hwa V, Chowen JA, Oxvig C, Rosenfeld RG, Pérez-Jurado LA, Argente J. Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability. EMBO Mol Med. 2016;8(4):363–74. https://doi.org/10.15252/emmm.201506106. 2. Babiker A, Al Noaim K, Al Swaid A, Alfadhel M, Deeb A, Martín-Rivada Á, Barrios V, Pérez-Jurado LA, Alfares A, Al Alwan I, Argente J. Short stature with low insulin-like growth factor 1 availability due to pregnancy-associated plasma protein A2 deficiency in a Saudi family. Clin Genet. 2021;100(5):601–6. https://doi.org/10.1111/cge.14030. 3. Argente J, Pérez-Jurado LA. Genetic causes of proportionate short stature. Best Pract Res Clin Endocrinol Metab. 2018;32(4):499–522. https://doi.org/10.1016/j.beem.2018.05.012. 4. Barrios V, Chowen JA, Martín-Rivada Á, Guerra-Cantera S, Pozo J, Yakar S, Rosenfeld RG, Pérez-Jurado LA, Suárez J, Argente J. Pregnancy-Associated plasma protein (PAPP)-A2 in physiology and disease. Cells. 2021;10(12):3576. https://doi.org/10.3390/cells10123576. 5. Muñoz-Calvo MT, Barrios V, Pozo J, Chowen JA, Martos-Moreno GÁ, Hawkins F, Dauber A, Domené HM, Yakar S, Rosenfeld RG, Pérez-Jurado LA, Oxvig C, Frystyk J, Argente J. Treatment with recombinant human insulin-like Growth Factor-1 improves growth in patients with PAPP-A2 Deficiency. J Clin Endocrinol Metab. 2016;101(11):3879–83. https://doi.org/10.1210/jc.2016-2751.
|
|